Welcome to our dedicated page for Adapthealth SEC filings (Ticker: AHCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicare reimbursement swings, rapid acquisitions, and intricate lease accounting make AdaptHealth Corp’s disclosures some of the most difficult in the home-health sector. If you have ever tried to locate segment revenue shifts or pinpoint when executives sell shares, you know the challenge of AdaptHealth SEC filings explained simply.
Stock Titan solves that complexity. Our AI reads each AdaptHealth annual report 10-K simplified and every AdaptHealth quarterly earnings report 10-Q filing the instant it hits EDGAR, highlighting reimbursement exposure, acquisition earn-outs, and goodwill adjustments. Real-time alerts surface AdaptHealth Form 4 insider transactions real-time, so you never miss crucial AdaptHealth executive stock transactions Form 4. Need headline context? Our platform turns dense 8-Ks into one-screen briefs—think “AdaptHealth 8-K material events explained”—while proxy digests spotlight AdaptHealth proxy statement executive compensation in clear terms.
Use cases span the entire investment workflow:
- Monitor AdaptHealth insider trading Form 4 transactions before major announcements.
- Run comparative AdaptHealth earnings report filing analysis across quarters without slogging through PDFs.
- Speed-read footnotes by understanding AdaptHealth SEC documents with AI—lease liabilities, DSO trends, and integration costs surfaced automatically.
Whether you’re tracking oxygen equipment margins or gauging cash-flow impact from new payer contracts, Stock Titan provides comprehensive coverage of every 10-K, 10-Q, 8-K, S-4, and Form 4—updated in real time and distilled into investor-ready language. Complex filings, clarified.
AdaptHealth Corp. (AHCO) reported Q3 2025 results. Net revenue was $820.3 million versus $805.9 million a year ago. Operating income was $61.7 million, and net income attributable to AdaptHealth was $24.5 million, or diluted EPS of $0.16 (vs. $0.15). Segment revenue totaled $354.8 million in Sleep Health, $177.0 million in Respiratory Health, $150.1 million in Diabetes Health, and $138.4 million in Wellness at Home.
On the balance sheet, long‑term debt (less current) was $1.74 billion and cash was $80.4 million as of September 30, 2025. Year‑to‑date, operating cash flow was $418.6 million, with a $32.2 million pre‑tax gain from the sale of two businesses closed on May 1 and June 9, 2025. For the nine months, depreciation and amortization (including patient equipment) was $284.4 million. As of October 31, 2025, there were 135,424,334 common shares outstanding.
David S. Williams III, a director of AdaptHealth Corp. (AHCO), sold 8,200 shares on 08/22/2025 at a weighted average price of $9.73 per share. The filing shows the reported sales occurred in multiple transactions at prices ranging from $9.60 to $9.85, and the reporting person continues to beneficially own 50,045 shares following the transactions. The Form 4 was filed by one reporting person and signed by an attorney-in-fact, with a previously filed power of attorney incorporated by reference.
AdaptHealth Corp. 10-Q (Q2 2025) Reports net revenue of $800.4M for Q2 2025 and $1.578B for the six months ended June 30, 2025, relative to $806.0M and $1.598B a year earlier.
Operating income improved to $79.3M in Q2 driven by a $32.225M gain on sale of businesses; however, higher income tax expense ($35.9M in Q2) contributed to a Q2 net income of $15.8M and six-month net income of $9.7M, down vs. prior periods.
- Adjusted EBITDA declined to $155.5M in Q2 and to $283.5M for six months.
- Cash declined to $68.63M from $109.75M at year-end.
- Long-term debt decreased to $1.793B from $1.965B (repayments of $175.0M noted).
- Disposed two Wellness at Home businesses for gross proceeds of $120.835M and recognized related goodwill reductions.
AdaptHealth Corp. (AHCO) – Form 4 insider activity
Director Theodore B. Lundberg reported two acquisitions of AdaptHealth common stock on 06/26/2025:
- 21,346 shares acquired
- 7,864 shares acquired
Both transactions are recorded at $0, indicating they were equity grants or similar non-cash awards rather than open-market purchases. Following the transactions, Lundberg’s direct beneficial ownership rose to 859,756 shares. No dispositions, derivative securities, or 10b5-1 plan designations were disclosed, and the filing lists a Power of Attorney (Exhibit 24) supporting the submission.
The Form 4 contains no additional financial metrics or narrative commentary.
FAQ
What is the current stock price of Adapthealth (AHCO)?
What is the market cap of Adapthealth (AHCO)?
